Your browser is no longer supported. Please, upgrade your browser.
iShares Genomics Immunology and Healthcare ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-7.06%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-15.84%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-2.82%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y15.74%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year42.45%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range22.32 - 55.03 Perf YTD-4.90%
Dividend0.11 P/FCF- EPS past 5Y- ROI- 52W High-20.61% Beta-
Dividend %0.25% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low95.75% ATR1.92
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)31.15 Volatility4.32% 3.39%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.88 Prev Close43.25
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume98.53K Price43.69
Recom- SMA20-12.92% SMA50-12.57% SMA2003.66% Volume185,480 Change1.02%
Feb-03-21 01:47PM  
May-18-20 03:42PM  
Dec-23-19 12:00PM  
Dec-18-19 01:41PM  
Nov-25-19 06:55PM  
Nov-21-19 12:56PM  
Nov-04-19 01:00PM  
Oct-23-19 10:10AM  
Sep-06-19 03:07PM  
Sep-04-19 03:18PM  
The investment seeks to track the investment results of the NYSE FactSet Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 90% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 10% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.